| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 50,820 | 34,100 | 8,110 | 6,560 | 4,040 |
| Sales Growth | +49.03% | +320.47% | +23.63% | +62.38% | -34.52% |
| Net Income | 125,210 | 16,610 | -32,490 | 1,070 | -4,210 |
| Net Income Growth | +653.82% | +151.12% | -3,136.45% | +125.42% | +31.21% |
Dominari Holdings Inc (DOMH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Dominari Holdings Inc. primarily focused on the development of a diverse portfolio of small-molecule anticancer and antiviral therapeutics and related patent technology. The Company's fintech and financial services business will be operated through its subsidiary, Dominari Financial Inc. Dominari Holdings Inc., formerly known as AIkido Pharma Inc., is based in NEW YORK.
Fiscal Year End Date: 12/31